ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Rating Lowered to Sell at BidaskClub
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.
Other analysts have also issued research reports about the stock. HC Wainwright initiated coverage on shares of ZIOPHARM Oncology in a research report on Thursday, June 1st. They set a “buy” rating and a $9.50 price target on the stock. ValuEngine upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, April 26th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. ZIOPHARM Oncology presently has a consensus rating of “Hold” and a consensus price target of $13.17.
ZIOPHARM Oncology (ZIOP) remained flat at $5.51 on Monday. 1,003,534 shares of the company’s stock traded hands. The stock’s 50 day moving average is $5.91 and its 200 day moving average is $6.34. ZIOPHARM Oncology has a 12 month low of $4.84 and a 12 month high of $7.88. The stock’s market capitalization is $774.88 million.
ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Monday, July 31st. The biotechnology company reported ($0.13) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.66 million. The firm’s quarterly revenue was down 5.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.01) EPS. On average, analysts predict that ZIOPHARM Oncology will post ($0.54) earnings per share for the current year.
Hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its stake in shares of ZIOPHARM Oncology by 18.4% in the fourth quarter. Wells Fargo & Company MN now owns 168,616 shares of the biotechnology company’s stock valued at $1,402,000 after buying an additional 26,233 shares during the period. Morgan Stanley raised its stake in shares of ZIOPHARM Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock valued at $13,447,000 after buying an additional 78,583 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of ZIOPHARM Oncology by 5.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 603,844 shares of the biotechnology company’s stock valued at $5,018,000 after buying an additional 28,576 shares during the period. Third Security LLC raised its stake in shares of ZIOPHARM Oncology by 0.3% in the fourth quarter. Third Security LLC now owns 9,692,403 shares of the biotechnology company’s stock valued at $80,544,000 after buying an additional 26,661 shares during the period. Finally, Capital Fund Management S.A. bought a new stake in shares of ZIOPHARM Oncology during the fourth quarter valued at about $348,000. Institutional investors and hedge funds own 38.17% of the company’s stock.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.